Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report

J R Passweg, H Baldomero, P Bader, C Bonini, R F Duarte, C Dufour, A Gennery, N Kröger, J Kuball, F Lanza, S Montoto, A Nagler, J A Snowden, J Styczynski, M Mohty

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record number of 42 171 HSCT in 37 626 patients (16 030 allogeneic (43%), 21 596 autologous (57%)) were reported by 655 centers in 48 countries in 2015. Trends include continued growth in transplant activity over the last decade, with the highest percentage increase seen in middle-income countries but the highest absolute growth in the very-high-income countries in Europe. Main indications for HSCT were myeloid malignancies 9413 (25%; 96% allogeneic), lymphoid malignancies 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is the decreasing use of allogeneic HSCT for CLL from 504 patients in 2011 to 255 in 2015, most likely to be due to new drugs. Use of haploidentical donors for allogeneic HSCT continues to grow: 2012 in 2015, a 291% increase since 2005. Growth is seen for all diseases. In AML, haploidentical HSCT increases similarly for patients with advanced disease and for those in CR1. Both marrow and peripheral blood are used as the stem cell source for haploidentical HSCT with higher numbers reported for the latter.

Original languageEnglish
Pages (from-to)811-817
Number of pages7
JournalBone Marrow Transplantation
Volume52
Issue number6
DOIs
Publication statusPublished - Jun 2017

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Bone Marrow
Transplants
Growth
Hematopoietic System
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Neoplasms
Surveys and Questionnaires
Stem Cells
Tissue Donors
Pharmaceutical Preparations

Keywords

  • Journal Article

Cite this

Use of haploidentical stem cell transplantation continues to increase : the 2015 European Society for Blood and Marrow Transplant activity survey report. / Passweg, J R; Baldomero, H; Bader, P; Bonini, C; Duarte, R F; Dufour, C; Gennery, A; Kröger, N; Kuball, J; Lanza, F; Montoto, S; Nagler, A; Snowden, J A; Styczynski, J; Mohty, M.

In: Bone Marrow Transplantation, Vol. 52, No. 6, 06.2017, p. 811-817.

Research output: Contribution to journalArticle

Passweg, JR, Baldomero, H, Bader, P, Bonini, C, Duarte, RF, Dufour, C, Gennery, A, Kröger, N, Kuball, J, Lanza, F, Montoto, S, Nagler, A, Snowden, JA, Styczynski, J & Mohty, M 2017, 'Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report', Bone Marrow Transplantation, vol. 52, no. 6, pp. 811-817. https://doi.org/10.1038/bmt.2017.34
Passweg, J R ; Baldomero, H ; Bader, P ; Bonini, C ; Duarte, R F ; Dufour, C ; Gennery, A ; Kröger, N ; Kuball, J ; Lanza, F ; Montoto, S ; Nagler, A ; Snowden, J A ; Styczynski, J ; Mohty, M. / Use of haploidentical stem cell transplantation continues to increase : the 2015 European Society for Blood and Marrow Transplant activity survey report. In: Bone Marrow Transplantation. 2017 ; Vol. 52, No. 6. pp. 811-817.
@article{a615c77bb2e94358b702e167e6f8d458,
title = "Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report",
abstract = "Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record number of 42 171 HSCT in 37 626 patients (16 030 allogeneic (43{\%}), 21 596 autologous (57{\%})) were reported by 655 centers in 48 countries in 2015. Trends include continued growth in transplant activity over the last decade, with the highest percentage increase seen in middle-income countries but the highest absolute growth in the very-high-income countries in Europe. Main indications for HSCT were myeloid malignancies 9413 (25{\%}; 96{\%} allogeneic), lymphoid malignancies 24 304 (67{\%}; 20{\%} allogeneic), solid tumors 1516 (4{\%}; 3{\%} allogeneic) and non-malignant disorders 2208 (6{\%}; 90{\%} allogeneic). Remarkable is the decreasing use of allogeneic HSCT for CLL from 504 patients in 2011 to 255 in 2015, most likely to be due to new drugs. Use of haploidentical donors for allogeneic HSCT continues to grow: 2012 in 2015, a 291{\%} increase since 2005. Growth is seen for all diseases. In AML, haploidentical HSCT increases similarly for patients with advanced disease and for those in CR1. Both marrow and peripheral blood are used as the stem cell source for haploidentical HSCT with higher numbers reported for the latter.",
keywords = "Journal Article",
author = "Passweg, {J R} and H Baldomero and P Bader and C Bonini and Duarte, {R F} and C Dufour and A Gennery and N Kr{\"o}ger and J Kuball and F Lanza and S Montoto and A Nagler and Snowden, {J A} and J Styczynski and M Mohty",
year = "2017",
month = "6",
doi = "10.1038/bmt.2017.34",
language = "English",
volume = "52",
pages = "811--817",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Use of haploidentical stem cell transplantation continues to increase

T2 - the 2015 European Society for Blood and Marrow Transplant activity survey report

AU - Passweg, J R

AU - Baldomero, H

AU - Bader, P

AU - Bonini, C

AU - Duarte, R F

AU - Dufour, C

AU - Gennery, A

AU - Kröger, N

AU - Kuball, J

AU - Lanza, F

AU - Montoto, S

AU - Nagler, A

AU - Snowden, J A

AU - Styczynski, J

AU - Mohty, M

PY - 2017/6

Y1 - 2017/6

N2 - Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record number of 42 171 HSCT in 37 626 patients (16 030 allogeneic (43%), 21 596 autologous (57%)) were reported by 655 centers in 48 countries in 2015. Trends include continued growth in transplant activity over the last decade, with the highest percentage increase seen in middle-income countries but the highest absolute growth in the very-high-income countries in Europe. Main indications for HSCT were myeloid malignancies 9413 (25%; 96% allogeneic), lymphoid malignancies 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is the decreasing use of allogeneic HSCT for CLL from 504 patients in 2011 to 255 in 2015, most likely to be due to new drugs. Use of haploidentical donors for allogeneic HSCT continues to grow: 2012 in 2015, a 291% increase since 2005. Growth is seen for all diseases. In AML, haploidentical HSCT increases similarly for patients with advanced disease and for those in CR1. Both marrow and peripheral blood are used as the stem cell source for haploidentical HSCT with higher numbers reported for the latter.

AB - Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record number of 42 171 HSCT in 37 626 patients (16 030 allogeneic (43%), 21 596 autologous (57%)) were reported by 655 centers in 48 countries in 2015. Trends include continued growth in transplant activity over the last decade, with the highest percentage increase seen in middle-income countries but the highest absolute growth in the very-high-income countries in Europe. Main indications for HSCT were myeloid malignancies 9413 (25%; 96% allogeneic), lymphoid malignancies 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is the decreasing use of allogeneic HSCT for CLL from 504 patients in 2011 to 255 in 2015, most likely to be due to new drugs. Use of haploidentical donors for allogeneic HSCT continues to grow: 2012 in 2015, a 291% increase since 2005. Growth is seen for all diseases. In AML, haploidentical HSCT increases similarly for patients with advanced disease and for those in CR1. Both marrow and peripheral blood are used as the stem cell source for haploidentical HSCT with higher numbers reported for the latter.

KW - Journal Article

U2 - 10.1038/bmt.2017.34

DO - 10.1038/bmt.2017.34

M3 - Article

C2 - 28287639

VL - 52

SP - 811

EP - 817

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -